Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy.
To assess the impact of highly active antiretroviral therapy (HAART) on the outcome of systemic human immunodeficiency virus-related non-Hodgkin lymphoma (HIV-NHL), we retrospectively analyzed 235 patients in whom HIV-NHL was diagnosed from April 1988 through December 1999. A multivariate Cox proportional hazards model was used to estimate prognostic factors for overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS). Complete remission occurred in 49% of patients, and the 3-year rates of OS, PFS, and DFS were 19%, 49%, and 73%, respectively. The greatest risk for shortened OS, PFS, and DFS was associated with no HAART use (compared with long-term HAART use); hazard ratios were 17.42 (95% confidence interval [CI], 17.42-40.25), 9.11 (95% CI, 3.71-22.32), and 8.54 (95% CI, 1.19-61.11), respectively. Our study suggests that the long-term use of HAART may favorably change the outcome for patients with systemic HIV-NHL.
Vaccher
Emanuela
E
Division of Medical Oncology A, National Cancer Institute, Aviano, Italy.
Spina
Michele
M
Talamini
Renato
R
Zanetti
Martina
M
di Gennaro
Giampiero
G
Nasti
Guglielmo
G
Tavio
Marcello
M
Bernardi
Daniele
D
Simonelli
Cecilia
C
Tirelli
Umberto
U
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D005260:Female; D006678:HIV; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000401:mortality*; D008228:Lymphoma, Non-Hodgkin / Q000209:etiology / Q000401:mortality*; D008297:Male; D017063:Outcome Assessment, Health Care; D011379:Prognosis